A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma
Authors:
Open Access
- 3 February 2020
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 9 (6) , 2134-2145
Abstract
Background: Although various prognostic models for primary central nervous system lymphoma (PCNSL) have been developed, there is no consensus regarding the optimal prognostic index. We aimed to evaluate potential prognostic factors and construct a novel predictive model for PCNSL patients.Methods: We enrolled newly diagnosed PCNSL patients between 2003 and 2015. The primary endpoint was progression‐free survival (PFS), and the secondary endpoint was overall survival (OS). The prognostic factors identified using multivariate Cox proportional hazards models were used to develop a predictive model. We subsequently validated the prognostic model in an independent cohort. We also evaluated the validity of the existing scores: the International Extranodal Lymphoma Study Group (IELSG), the Nottingham/Barcelona (NB), and the Memorial Sloan‐Kettering Cancer Center models (MSKCC).Results: We identified 101 patients with newly diagnosed PCNSL at our center. Multivariate analysis showed that age ≥80, deep brain lesions, and ECOG ≥2 were independent risk factors of PFS. Assigning one point for each factor, we constructed a novel prognostic model, the Taipei Score, with four distinct risk groups (0‐3 points). The performances of the Taipei Score in discriminating both PFS and OS in the training cohort were significant, and the score was validated in the external validation cohort. The IELSG, NB and MSKCC models had insufficient discriminative ability for either PFS or OS in both cohorts.Conclusion: The Taipei Score is a simple model that discriminates PFS and OS for PCNSL patients. The score may offer disease risk stratification and facilitate clinical decision‐making.Keywords
Funding Information
- Ministry of Science and Technology (MOST 104‐2314‐B‐075‐085‐MY2, MOST 105‐2314‐B‐418‐003‐MY3)
- Taiwan Clinical Oncology Research Foundation
This publication has 40 references indexed in Scilit:
- Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)Journal of Clinical Oncology, 2013
- Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantationHaematologica, 2013
- Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer CenterNeuro-Oncology, 2012
- Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRIClinical Cancer Research, 2012
- Age, gender, and racial differences in incidence and survival in primary CNS lymphomaBritish Journal of Cancer, 2011
- Primary central nervous system lymphomaCurrent Opinion in Neurology, 2009
- Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA)Annals of Oncology, 2009
- Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic ModelJournal of Clinical Oncology, 2006
- Trends in survival from primary central nervous system lymphoma, 1975–1999Cancer, 2005
- Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004